1. Home
  2. NCMI vs NGNE Comparison

NCMI vs NGNE Comparison

Compare NCMI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$3.16

Market Cap

306.0M

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$28.13

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
NGNE
Founded
2005
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.0M
327.8M
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
NCMI
NGNE
Price
$3.16
$28.13
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$5.63
$63.57
AVG Volume (30 Days)
271.4K
117.8K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
3.36%
N/A
EPS Growth
52.17
0.93
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.20
N/A
Revenue Next Year
$6.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$14.65
52 Week High
$5.53
$37.27

Technical Indicators

Market Signals
Indicator
NCMI
NGNE
Relative Strength Index (RSI) 47.19 52.63
Support Level $2.86 $19.23
Resistance Level $3.76 $29.05
Average True Range (ATR) 0.14 1.86
MACD 0.00 -0.49
Stochastic Oscillator 41.14 26.18

Price Performance

Historical Comparison
NCMI
NGNE

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: